These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38191582)

  • 41. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
    Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
    BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
    Taheri S
    Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
    Li H; Huang Q; Zhang Y
    Hum Vaccin Immunother; 2023 Dec; 19(3):2291900. PubMed ID: 38112002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
    Wu LS; Su Y; Li C; Zhou W; Jackson CC; Sun YN; Zhou H
    Clin Transl Sci; 2022 Dec; 15(12):3000-3011. PubMed ID: 36204820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
    Futami M; Suzuki K; Kato S; Ohmae S; Tahara Y; Nojima M; Imai Y; Mimura T; Watanabe Y; Tojo A
    PLoS One; 2020; 15(4):e0231896. PubMed ID: 32320454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial.
    Shao M; Yu Q; Teng X; Guo X; Wei G; Xu H; Cui J; Chang AH; Hu Y; Huang H
    Bone Marrow Transplant; 2021 Jul; 56(7):1642-1650. PubMed ID: 33608658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
    Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
    Front Immunol; 2022; 13():997589. PubMed ID: 36131934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
    Jatiani SS; Aleman A; Madduri D; Chari A; Cho HJ; Richard S; Richter J; Brody J; Jagannath S; Parekh S
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):632-636.e1. PubMed ID: 32553791
    [No Abstract]   [Full Text] [Related]  

  • 53. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro.
    Zhang H; Lv X; Kong Q; Tan Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.
    Wang L; Hong R; Zhou L; Wang Y; Lv Y; Ni F; Zhang M; Zhao H; Ding S; Chang AH; Xu H; Hu Y; Wei G; Huang H
    Cytotherapy; 2023 Feb; 25(2):192-201. PubMed ID: 36496302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
    Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
    Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
    Liu Y; Jie X; Nian L; Wang Y; Wang C; Ma J; Jiang J; Wu Q; Qiao J; Chen W; Cao J; Yan Z; Shi M; Cheng H; Zhu F; Sang W; Li D; Chen C; Xu K; Li Z
    Front Immunol; 2023; 14():1169071. PubMed ID: 37153543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.